评估皮下和口服robenacoxib meloxicam治疗急性疼痛和炎症与整形外科手术的狗。

文章的细节

引用

复制到剪贴板

Gruet P, Seewald W,王约

评估皮下和口服robenacoxib meloxicam治疗急性疼痛和炎症与整形外科手术的狗。

兽医研究》2011年2月,72 (2):184 - 93。doi: 10.2460 / ajvr.72.2.184。

PubMed ID

21281192 (在PubMed

]

文摘

目的:评估疗效和耐受性的robenacoxib控制狗接受整形手术的疼痛和炎症。动物:140 client-owned狗。程序:多中心、前瞻性、随机、盲法进行了现场试验比较robenacoxib(97只)和meloxicam狗(43)。随机化后,每个狗收到一个初始剂量(robenacoxib 2毫克/公斤;meloxicam, 0.2毫克/公斤)通过SC注射手术前和每日剂量(robenacoxib, 1 - 2毫克/公斤;meloxicam, 0.1毫克/公斤)的口服药物,手术后15天。疗效评估的兽医和业主通过数字等级量表和视觉模拟尺度。安全评估报告不良事件的基础上,临床症状,血液和生化分析的结果,和颊粘膜出血时间。结果:治疗组平衡对基线和人口统计数据。两种治疗方法提供了类似的足够的疼痛控制,与修改格拉斯哥疼痛评估量表作为支持的主要终点和次要终点在评估由兽医和主人。 For the primary end point, the ratio of the reciprocal of the scores for robenacoxib to meloxicam was 1.16 (95% confidence interval, 0.98 to 1.37). No dogs required rescue analgesia. Both treatments were associated with only minor adverse events, which were not necessarily related to the administered treatments and did not affect mucosal bleeding times. CONCLUSIONS AND CLINICAL RELEVANCE: Robenacoxib provided efficacy and tolerability similar to those of meloxicam for the management of perioperative pain and inflammation in dogs undergoing orthopedic surgery.

DrugBank数据引用了这篇文章

药物

Robenacoxib